ABVC BioPharma, Inc. (ABVC)
Nasdaq · Healthcare · Biotechnology
$0.98−2.97%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $26.2M
- 52-week range
- $0.707 – $3.40
- 52-week change
- −68.63%
- EPS (trailing)
- −$0.30
Fiscal year to Dec 2025
- Revenue
- $296K (−41.91%)
- Net income
- −$7.9M
- Operating margin
- −2416.0%
- Diluted EPS
- −$0.39
From the company’s annual report on SEC EDGAR.
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer.
Headquarters: Fremont, United States · 16 employees · abvcpharma.com